Xenon Pharmaceuticals Inc (XENE)

$55.23 -2.67 (-4.61%)
Market Cap 4.59B
Revenue (ttm) 7.50M
Net Income (ttm) -345.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,612.13%
Debt to Equity Ratio 0.00
Volume 3,850,000
Avg Vol 1,423,826
Day's Range N/A - N/A
Shares Out 83.19M
Stochastic %K 62%
Beta 0.91
Analysts Strong Sell
Price Target $78.31

Company Profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as majo...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 484 3300
Address:
200-3650 Gilmore Way, Burnaby, Canada
InTheMoney_
InTheMoney_ Mar. 15 at 6:19 AM
$XENE $SPY NOTHING but selling by insiders https://finshort.com/XENE/insiders
1 · Reply
Lanuchbox
Lanuchbox Mar. 15 at 2:20 AM
$XENE
0 · Reply
Lanuchbox
Lanuchbox Mar. 13 at 2:34 AM
$XENE Check out this video summary https://youtu.be/mHJ1SNjE3lc?si=diZmKBQXl7Mkihaz
0 · Reply
jayessbee
jayessbee Mar. 11 at 8:29 PM
$XENE Started a position today... best in class efficacy, no titration, cash, and three Ph3 programs-- seemingly unpriced value... GLTA...
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 11 at 6:22 PM
Xenon Pharmaceuticals May Have a New Answer for Epilepsy https://jlsfund.substack.com/p/xenon-pharmaceuticals-may-have-a $XENE
0 · Reply
rob70
rob70 Mar. 11 at 3:29 PM
$XENE Can't seem to break 61 today...decent volume though.
1 · Reply
Quantumup
Quantumup Mar. 11 at 1:09 PM
BTIG⬆️the PT on $RAPP to $53 from $47 and reiterated at a Buy rating. $XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities. Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with $490.5M in cash and equiv, funding operations into 2H29.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 11:08 AM
$XENE Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.
0 · Reply
rob70
rob70 Mar. 11 at 10:13 AM
$XENE $57 per share offering price. Not too bad. 9% under Monday’s close.
0 · Reply
Nerevarine
Nerevarine Mar. 10 at 5:28 PM
$XENE 500 mil offering? no problem! Lets gooo
1 · Reply
Latest News on XENE
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mar 12, 2026, 4:01 PM EDT - 3 days ago

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Mar 10, 2026, 10:39 PM EDT - 5 days ago

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Xenon Pharmaceuticals Announces Proposed Public Offering

Mar 9, 2026, 4:01 PM EDT - 6 days ago

Xenon Pharmaceuticals Announces Proposed Public Offering

Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge

Mar 9, 2026, 2:50 PM EDT - 6 days ago

Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge

Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript

Mar 9, 2026, 2:17 PM EDT - 6 days ago

Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript

Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked

Mar 9, 2026, 11:56 AM EDT - 6 days ago

Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked

Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures

Mar 9, 2026, 9:26 AM EDT - 6 days ago

Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Mar 9, 2026, 7:26 AM EDT - 6 days ago

Xenon Pharma's epilepsy drug meets main goal in late-stage trial

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

Mar 9, 2026, 7:00 AM EDT - 6 days ago

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Mar 8, 2026, 2:00 PM EDT - 7 days ago

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 4:01 PM EST - 17 days ago

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study

Jan 20, 2026, 8:46 AM EST - 7 weeks ago

Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 4:05 PM EST - 2 months ago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 4:15 PM EST - 2 months ago

Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 2 months ago

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 2 months ago

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout

Dec 18, 2025, 5:30 AM EST - 3 months ago

Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Dec 10, 2025, 4:22 PM EST - 3 months ago

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Dec 5, 2025, 9:00 AM EST - 3 months ago

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Dec 3, 2025, 8:30 AM EST - 3 months ago

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Nov 25, 2025, 8:30 AM EST - 3 months ago

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon to Present at Upcoming Investor Conferences

Nov 6, 2025, 8:30 AM EST - 4 months ago

Xenon to Present at Upcoming Investor Conferences

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 2:06 AM EST - 4 months ago

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Nov 3, 2025, 4:01 PM EST - 4 months ago

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Xenon to Report Q3 2025 Financial Results on November 3, 2025

Oct 27, 2025, 8:30 AM EDT - 4 months ago

Xenon to Report Q3 2025 Financial Results on November 3, 2025

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Xenon Pharmaceuticals Inc. - Special Call

Oct 6, 2025, 3:45 PM EDT - 5 months ago

Xenon Pharmaceuticals Inc. - Special Call

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

Sep 25, 2025, 4:01 PM EDT - 6 months ago

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release

Aug 12, 2025, 2:48 PM EDT - 7 months ago

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:44 PM EDT - 7 months ago

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Xenon to Report Q2 2025 Financial Results on August 11, 2025

Aug 4, 2025, 8:01 AM EDT - 7 months ago

Xenon to Report Q2 2025 Financial Results on August 11, 2025

Xenon Joins the Russell 3000® and Russell 2000® Indexes

Jun 27, 2025, 4:01 PM EDT - 9 months ago

Xenon Joins the Russell 3000® and Russell 2000® Indexes

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 4:01 PM EDT - 10 months ago

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum

May 15, 2025, 8:49 AM EDT - 10 months ago

Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 4:01 PM EDT - 10 months ago

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:06 PM EDT - 10 months ago

Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 10 months ago

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

Xenon to Report Q1 2025 Financial Results on May 12, 2025

May 5, 2025, 4:01 PM EDT - 11 months ago

Xenon to Report Q1 2025 Financial Results on May 12, 2025

Xenon- A Later Stage Story

Apr 18, 2025, 3:36 AM EDT - 11 months ago

Xenon- A Later Stage Story

Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data

Apr 4, 2025, 4:23 PM EDT - 1 year ago

Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Apr 4, 2025, 8:30 AM EDT - 1 year ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 1 year ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY RYTM VRTX

Xenon to Present at Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:01 PM EDT - 1 year ago

Xenon to Present at Stifel 2025 Virtual CNS Forum

Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:53 PM EST - 1 year ago

Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

Feb 27, 2025, 4:01 PM EST - 1 year ago

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Feb 25, 2025, 4:01 PM EST - 1 year ago

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

Feb 20, 2025, 4:01 PM EST - 1 year ago

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region

Feb 12, 2025, 12:00 PM EST - 1 year ago

XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region

InTheMoney_
InTheMoney_ Mar. 15 at 6:19 AM
$XENE $SPY NOTHING but selling by insiders https://finshort.com/XENE/insiders
1 · Reply
Lanuchbox
Lanuchbox Mar. 15 at 2:20 AM
$XENE
0 · Reply
Lanuchbox
Lanuchbox Mar. 13 at 2:34 AM
$XENE Check out this video summary https://youtu.be/mHJ1SNjE3lc?si=diZmKBQXl7Mkihaz
0 · Reply
jayessbee
jayessbee Mar. 11 at 8:29 PM
$XENE Started a position today... best in class efficacy, no titration, cash, and three Ph3 programs-- seemingly unpriced value... GLTA...
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 11 at 6:22 PM
Xenon Pharmaceuticals May Have a New Answer for Epilepsy https://jlsfund.substack.com/p/xenon-pharmaceuticals-may-have-a $XENE
0 · Reply
rob70
rob70 Mar. 11 at 3:29 PM
$XENE Can't seem to break 61 today...decent volume though.
1 · Reply
Quantumup
Quantumup Mar. 11 at 1:09 PM
BTIG⬆️the PT on $RAPP to $53 from $47 and reiterated at a Buy rating. $XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities. Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with $490.5M in cash and equiv, funding operations into 2H29.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 11:08 AM
$XENE Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00 The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.
0 · Reply
rob70
rob70 Mar. 11 at 10:13 AM
$XENE $57 per share offering price. Not too bad. 9% under Monday’s close.
0 · Reply
Nerevarine
Nerevarine Mar. 10 at 5:28 PM
$XENE 500 mil offering? no problem! Lets gooo
1 · Reply
paid2win
paid2win Mar. 10 at 4:17 PM
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy - BioPharma Dive $XENE https://stocks.apple.com/ANt5IvfLHQpe8NLXu0AJncg
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 3:56 PM
$XENE surging after a major clinical win — is this biotech setting up for a bigger move? 🚀 Phase III X-TOLE2 showed azetukalner significantly reduced focal onset seizure frequency, hitting the study’s primary goal and sending shares higher. The company is now planning an NDA filing in Q3 2026, putting the regulatory path in focus. See what this trial result could mean for the story 👉 https://www.zacks.com/stock/news/2881698/xene-stock-up-as-azetukalner-meets-goal-in-focal-onset-seizures-study?cid=sm-stocktwits-2-2881698-teaser-36782&ADID=SYND_STOCKTWITS_TWEET_2_2881698_TEASER_36782
0 · Reply
rob70
rob70 Mar. 10 at 3:30 PM
$XENE anemic volume. On pace for 15% of yesterday
0 · Reply
ZacksResearch
ZacksResearch Mar. 10 at 2:56 PM
$XENE surges 49.6% on breakthrough Phase III results! 🚀 The X-TOLE2 study hit its primary endpoint with a 42.7% placebo-adjusted reduction in FOS frequency for the 25 mg group. Xenon plans an NDA submission to the FDA by Q3 2026 for azetukalner, which could become a preferred treatment for epilepsy. Discover the full story here 👉 https://www.zacks.com/stock/news/2881698/xene-stock-up-as-azetukalner-meets-goal-in-focal-onset-seizures-study?cid=sm-stocktwits-2-2881698-body-36780&ADID=SYND_STOCKTWITS_TWEET_2_2881698_BODY_36780
0 · Reply
rob70
rob70 Mar. 10 at 1:36 PM
$XENE sub 60...getting ugly
1 · Reply
paid2win
paid2win Mar. 10 at 12:50 PM
$XENE Deutsche Bank Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $90 Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $56 to $90.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 10 at 12:45 PM
$XENE (-2.1% pre) Xenon Pharmaceuticals announces $500 million public offering https://ooc.bz/l/96141
0 · Reply
DFWAeroSpaceEngineer
DFWAeroSpaceEngineer Mar. 10 at 12:01 PM
$XENE yeah, there we go
0 · Reply
erevnon
erevnon Mar. 10 at 11:58 AM
Deutsche Bank maintains Xenon Pharmaceuticals $XENE at Buy and raises the price target from $56 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Gemmaells_
Gemmaells_ Mar. 10 at 8:46 AM
$XENE biotech coil looks constructive, if bu
0 · Reply
Liveforonce
Liveforonce Mar. 10 at 6:23 AM
$BATL $OLOX $XENE $CAMP if you have time, take a look at $NFE. They just had some interesting news that just came out and this could be the next runner. Good luck to all on your investments. Cheers!
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 10 at 3:28 AM
$XENE Huge volume spike on Mar 9 with 11.4M shares traded as price hit $62.76, way above the average volume of 979,068. Price surged from $41.94 on Mar 6 to $62.76. Smart move is to wait for a lower H% before considering entry.
0 · Reply